Journal: Scientific Reports
Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma
doi: 10.1038/s41598-019-52356-6
Figure Lengend Snippet: Serum MFG-E8 levels in patients with liver diseases. Serum milk fat globule-EGF factor 8 (MFG-E8) levels are shown for healthy volunteers (HVs) and hepatocellular carcinoma (HCC) patients ( A ), for HCC patients stratified by tumor size ( B ) by etiology of liver diseases ( C ), for hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected, post-sustained virologic response (SVR) and non-alcoholic fatty liver disease (NAFLD) patients with chronic hepatitis (CH), liver cirrhosis (LC), and HCCs ( D ), and in patients with benign liver tumors (Benign), intrahepatic cholangiocarcinoma (ICC), or metastatic liver tumors derived from primary colon cancer (Meta) ( D ) and for HCC patients before and after surgery (solid line, n = 12) or radiofrequency ablation (dashed line, n = 7) ( E ). Box plots represent the interquartile range and whiskers show minimum and maximum values. The line in each box shows the median. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, † p < 0.0001 compared with HV by Kruskal-Wallis test with Dunn’s multiple comparison test. Paired Student’s t test was used for the analysis presented in ( E ).
Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.
Techniques: Virus, Infection, Derivative Assay, Comparison